Artificial intelligence (AI) isn’t just for humiliating chess masters and Jeopardy champions, a la IBM’s Watson supercomputer. AI is already being used widely for routine tasks.Two weeks ago Zendesk (NYSE: ZEN) launched its new Automatic Answers service that answers emails from customers. The system isn’t just an autoresponder, though. It… Read More

When we launched Breakthrough Tech Profits two months ago, we knew our stock picks were good, but we also thought our timing was, too. We expected a flood of investor money would soon flow into technology-intensive companies that could generate bigger profits in a stagnant global economy. Still, we didn’t… Read More

It wasn’t long ago that investors couldn’t run away from Western Digital (WDC) fast enough. The darling of contrarian tech investors only two years ago as its share price soared above $100, rapidly declining sales of PCs during the past year and concerns over the price Western Digital paid to… Read More

I’m not going to lie; I have absolutely no idea what a Pokémon is aside from some sort of cartoonish character used in a popular video game. Judging from my newsfeed nothing else has happened in the world since the augmented reality game Pokémon Go was released earlier this month,… Read More

This could be the final boarding call for buyers of Ambarella Inc. (Nasdaq: AMBA), a global leader in high-speed video chip technology, as the stock is approaching the top of our recommended buy range of $57 and looks ready to make its way toward the $60-plus area. Turnaround ProceedsI like Ambarella’s… Read More

McKesson Corp. is underappreciated, under the radar and contrarian; which is exactly why I like it. Read More

All three of our cancer immunotherapy stocks made major announcements recently, but its still too soon to say which one will end up being the big winner. Read More

Smart cars aren’t just an American or European project. NXP Semiconductors (NSDQ: NXPI) just announced it is partnering with Tongjo University in China to be the country’s first ever road test initiative for smart cars. Read More

While most investors have been fixated on the outcome of the Brexit vote over the past ten days, there was good news regarding a couple of the “Top Tech Takeover Targets” that I identified in our most recent issue of Breakthrough Tech Profits. Read More

Emergent BioSolutions (NYSE: EBS), a biotech company specializing in vaccines and bioterrorism related products, lost more than 25 percent of its value in one trading day on June 22nd.  Details on why this happened and what the future would bring were sketchy at first but are slowly becoming available.  Only… Read More

Shares of Mobileye (NSDQ: MBLY) have been climbing following the announcement that it will be joining with Intel (NSDQ: INTC) and BMW to produce self-driving vehicles. Mobileye will be providing chips, sensors and software for the vehicles, including its EyeQ5 system and its Road Experience Management system, which provide precise… Read More

Global stock markets crashed and burned last week after the U.K. voted to leave the European Union, and it is not without reason to expect further losses over the next few days and weeks. Already the situation has become fluid with evidence of potential backtracking and softening of the rhetoric,… Read More

While the rest of the world was focused on the outcome of the “Brexit” vote last week, a couple of our Special Situations Portfolio stocks reported good news that may have been overlooked. Along with the overall decline in the stock market as a result of Great Britain’s decisions to… Read More

Following the Brexit vote, most of our holdings have declined more or less in line with the broader tech sector. Given how turbulent the global markets are, that’s really not much of a surprise. That said, two of our holdings have taken bigger hits than the others, largely thanks to… Read More

One of the best things you can hope for when you start buying lesser known technology stocks is that they attract more interest, which is exactly what is happening with Trimble Navigation. Read More

Despite its erratic trading behavior, thus far Argos has lived up to our expectations in terms of achieving its business objectives. And with an additional $30 million in cash to fund its operations, we see no reason to change our long term view on the company’s growth prospects. Read More

As markets become more volatile, it’s worthwhile to consider ways to protect long term portfolio holdings as well as how to profit in down markets.  Read More

Profit from turnarounds, acquisitions and trends. Read More

Argos Therapeutics (ARGS), a clinical research stage biotech company focusing on the personalized treatment of various cancers based on rallying the individual’s own immune system through its proprietary Arcelis platform, released interim test results this morning on the company’s ongoing Phase 3 ADAPT trial of its AGS-003 compound which met… Read More

Cerus Corp. (CERS), a provider of a leading system for blood infection control, and Rollins Inc. (ROL), a global leader in pest control, may gain ground if the Zika virus creates a health emergency as the summer heats up and the effects of the spring rains and travel patterns increase… Read More